Drug Profile

Research programme: dipiperidine anti-infectives/anti-inflammatories - Sequella

Alternative Names: SQ 609

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sequella
Class Adamantanes; Piperidines; Small molecules
Mechanism of Action Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

No development reported Crohn's disease; Severe acute respiratory syndrome; Tuberculosis

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in USA (PO)
24 Sep 2012 SQ 609 is available for licensing as of 24 Sep 2012. http://www.sequella.com/
12 Sep 2012 SQ 609 is still in Preclinical trials for Tuberculosis in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com